Core Insights - Eupraxia Pharmaceuticals announced positive 52-week follow-up data from its Phase 1b/2a RESOLVE trial for EP-104GI, a treatment for eosinophilic esophagitis (EoE), highlighting its potential as a once-a-year treatment option [1][2] Group 1: Trial Results - Cohorts 5 and 6 are the only groups to have reached 52 weeks in the RESOLVE trial, showing durable clinical symptom responses [3] - In Cohort 6, 2 out of 3 patients achieved clinical remission 52 weeks post-treatment, while 4 out of 6 patients from both Cohorts 5 and 6 remained in clinical remission [3] - At week 36, 67% of patients measured were in clinical remission, with no serious adverse events reported across over 200 patient-months of follow-up [3][4] Group 2: Symptom Improvement - In Cohort 6, patients experienced an average reduction in the Straumann Dysphagia Index (SDI) scores of -3.7, equating to a 58% improvement at week 52 [4] - Across Cohorts 5-7, the average reduction in SDI scores was -3.0, or 53%, at week 36, while 79% of patients in Cohorts 4-8 were in clinical remission at week 24 [4] Group 3: Pharmacokinetics - Plasma levels of fluticasone in Cohort 6 remained stable and predictable over 52 weeks, significantly lower than levels typically seen with daily asthma inhalers [4] - No serious adverse events or cases of oral or gastrointestinal candidiasis were reported during the trial [4] Group 4: Future Developments - The Phase 2b part of the RESOLVE trial is currently recruiting participants, with top-line data expected in Q3 2026 [8] - Eupraxia plans to disclose additional data from the ongoing RESOLVE trial in the coming months [7]
Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI